Company News
Jilin Province Expert Delegation Visits Heer Medical for Exchange and Discussion
In April 2018, Heer Medical organized a visit and exchange for a delegation of over 30 pathology and gynecology experts from Jilin Province, inviting nationally renowned cytopathology expert Prof. Yu Xiaomeng to deliver a lecture and showcasing DNA ploidy detection technology, which received high praise from all attending experts.
From April 20 to 22, 2018, Wuhan Heer Medical Technology Development Co., Ltd. (hereinafter "Heer Medical"), a subsidiary of Boai Xinkaiyuan Medical Technology Group Co., Ltd. (Stock Code: 300109), organized a visit and exchange for a delegation of over 30 pathology and gynecology experts from Jilin Province, and invited nationally renowned cytopathology expert Prof. Yu Xiaomeng to deliver a lecture.
Mr. Ren Dalong, Vice President of Xinkaiyuan Group and Founder of Heer Medical, delivered a warm welcome address to all guests attending this conference.
Heer Medical Chairman Mao Haizhan introduced the company's growth history to the assembled experts. After ten years of navigating the tides of the times, Heer Medical has boldly drawn its sword, built on deep foundations, and is ready to make its mark. Multiple carefully developed new products are about to come to market!
Prof. Yu Xiaomeng elaborated on the disease progression of cervical cells, the origins and principles of DNA ploidy analysis, and expressed full confidence and enthusiasm for the future precision of cervical cancer screening and its broad application in "two-cancer" screening programs.
Prof. Wu Guangping gave a vivid introduction to the current state of AI technology applications in medical development, highly affirming the enormous role Heer Medical's DNA ploidy technology has played in cervical cancer screening in recent years. Prof. Tian Lixiang presided over the expert discussion session, during which questions and answers were exchanged with great intensity. All agreed that the prospects for applying DNA ploidy AI technology to cervical cancer screening are exceedingly bright.
Gynecology expert representative Wang Yongxin voiced the clinical perspective: Heer Medical's technology enables earlier and more accurate detection of cervical lesions, guiding clinicians to intervene and treat disease progression promptly. This is of great significance for treatment outcomes and prognosis, and is truly a boon for patients!
After the conference, all guests toured Heer Medical's standardized laboratory and modern production workshop. Heer Medical's innovative technology, advanced diagnostics, and comprehensive after-sales service received unanimous praise from all attendees.
The cervix is a vital organ in the female reproductive system, deeply tied to every woman's lifelong health and family well-being. Through Heer Medical's independently developed DNA ploidy detection technology, it is possible to determine whether a patient has cancer or a general gynecological condition, achieving early detection, early diagnosis, early treatment, and early recovery!